Showing 3851-3860 of 5910 results for "".
- Canyon Labs Acquire's iuvo BioScience’s Lab Services and Consulting Businesseshttps://modernod.com/news/canyon-labs-acquires-iuvo-biosciences-lab-services-and-consulting-businesses/2482600/Canyon Labs, a provider of analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, has acquired the laboratory services and scientific consulting divisions of iuvo BioScience, a provider of ophthalmic medical device and pharmaceutical cli
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Regeneron Acquires UK-Based Biotech Oxularhttps://modernod.com/news/regeneron-acquires-uk-based-biotech-oxular/2482596/Regeneron has acquired Oxular, a clinical stage company making ocular delivery technology for retinal disorders. The news of the aquisition was made from a LinkedIn
- VisionGift Announces the Retirement of Longtime Medical Director, Mark Terry, MDhttps://modernod.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/VisionGift, a nonprofit dedicated ot ocular donation and corneal transplantation, announced the retirement of its medical director Mark Terry, MD, after 34 years of dedicated service to the field of eye banking. Succeeding him in this role will be Winston Chamberlain, MD, PhD, and
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Tenpoint and Visus Complete Mergerhttps://modernod.com/news/tenpoint-and-visus-complete-merger/2482576/Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- The Centre for Eye and Vision Research and SCOPE Health Partner to Innovate Ocular Surface Disease Solutionshttps://modernod.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have signed a Memorandum of Understanding (MoU) to collaborate on technologies to treat dry eye disease and other ocular surface conditions. The partnership aims to address unmet needs in eye care by leveraging SCOPE&rs